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Multiple endocrine neoplasia type 1 (MEN1) is an auto-
somal dominantly inherited syndrome. MEN1 is characterized
by the presence of functioning and nonfunctioning tumors or
hyperplasia of the pituitary gland, parathyroid glands, and
pancreatic islet cells. In addition, MEN1 carriers can have
adrenal or thyroid tumors and non-endocrine tumors, such as
lipomas, angiofibromas, and leiomyomas. Although leiomyoma
is not a major component of MEN1, it is thought to occur
more frequently than expected. However, there has been no
report of a case of MEN1 with leiomyoma in Korea so far.
This report describes a patient with multiple leiomyomas in
MEN1. A 50-year-old woman was referred for further evalua-
tion of elevated calcium levels and osteoporosis. Biochemical
abnormalities included hypercalcemia with elevated parathyroid
hormone. There was hyperprolactinemia with pituitary micro-
adenoma in sella MRI. An abdominal MRI demonstrated
adrenal nodules and leiomyomas in the bladder and uterus.
Endoscopic ultrasonography demonstrated esophageal
leiomyoma and pancreatic islet cell tumor. A subtotal para-
thyroidectomy with thymectomy was performed. Sequencing
of the MEN1 gene in this patient revealed a novel missense
mutation (D350V, exon 7). This is the first case of MEN1
accompanied with multiple leiomyomas, parathyroid adenoma,
pituitary adenoma, pancreatic tumor, and adrenal tumor.
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INTRODUCTION
Multiple endocrine neoplasia type 1 (MEN1) is
an autosomal dominant hereditary disorder. The
clinical diagnosis of MEN1 can be made in a
patient who has tumors in at least two of the
following tissues: pituitary, parathyroid, and
pancreatic islet cells. In addition, MEN1 carriers
can have adrenal or thyroid adenomas, bronchial
or thymic carcinoid tumors, and non-endocrine
tumors, such as lipomas, angiofibromas, collage-
nomas, and leiomyomas.
1-4 In Korean literature,
Oh et al. reported the first case in 1986, diagnosed
radiologically, and a total of 24 cases have been
reported since. Nevertheless, MEN1 cases with
accompanying multiple leiomyoma have not yet
been reported in Korean literature.
5-18 Recently, a
case of MEN1 was identified with accompanying
leiomyomas in the bladder, the uterus, and the
esophagus, in addition to typical endocrine tu-
mors, such as parathyroid adenoma, pituitary
adenoma, pancreatic tumor, and adrenal cortical
tumor. This report describes this MEN1 patient
with multiple leiomyomas, who revealed a novel
germline missense mutation, D350V, in the MEN1
gene, with a review of the relevant literature.
CASE REPORT
A 50-year-old female presented with chronic
fatigue. The patient was diagnosed with osteo-
porosis five years prior and was taking alendro-
nate. Hypercalcemia was diagnosed two years fol-
lowing the osteoporosis diagnosis, and the patient
visited the hospital for a comprehensive check-up.
The patient did not have any history of diabetes,
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hypertension, tuberculosis, or hepatitis. She was
the first daughter of two sons and two daughters.
Concurrently, her 81-year-old mother, who was
bedridden for unknown reasons, was also under-
going tests for hypercalcemia, and was subse-
quently diagnosed with multiple parathyroid ade-
nomas and pancreatic tumors, based on the test
results. Her father had a history of sudden death
by an acute cardiac event.
In the neck examination, the thyroid was not
enlarged, and palpable tumors were absent. Heart
and lung sounds were normal, and no abnor-
malities were detected in the abdomen, all ex-
tremities, or neurological tests. The axillary hair
and the pubic hair were normal, hirsutism was
absent, and galactorrhea was not observed.
In blood electrolyte tests, sodium was 144
mmol/L, potassium was 4.0 mmol/L, chloride was
107 mmol/L, blood calcium was 12.6 mg/mL,
ionized calcium was 5.4 mg/dL, and inorganic
phosphate was 3.3 mg/dL. In general biochemical
tests, fasting blood glucose was 93 mg/dL, blood
urea nitrogen was 8.9 mg/dL, creatinine was 0.8
mg/dL, and the hepatic function test was normal.
Her 24-hour urinary calcium excretion was 326
mg/day, the amount of phosphate excretion was
460 mg/day, and the creatinine clearance rate was
64 mL/min. Thyroid hormone tests were within
normal range, and intact-PTH was increased to
99.8 pg/mL. Prolactin was also mildly increased
to 27.63 ng/mL. Plasma insulin was 9.2 uIU/mL
(4.2 - 48), gastrin was 21 pg/mL (0 - 90), glucagon
was 40 pg/mL (40 - 130), pancreatic polypeptide
was 79 pmol/L (< 100), and vasoactive intestinal
polypeptide was 32 pg/mL (< 100). In dual X-ray
absorptiometry (DXA), the T score of the femur
was decreased to - 2.0, confirming the osteopenia
finding.
In the neck ultrasound, in the posterior area of
the left thyroid, a tumor suspected to be a
parathyroid adenoma 10 mm in size was detected,
and in the parathyroid scan, uptake was detected
in two glands (Fig. 1). In the neck computed
tomography (CT), parathyroid tumors, 10 mm in
the left side and 8 mm in the right side, were
detected. In the chest CT, abnormal findings in
the lung and the mediastinum were not detected.
On the brain magnetic resonance imaging (MRI),
a tumor 7 mm in size in the pituitary was detected
(Fig. 2). On the abdominal MRI, a 2.3 cm left ad-
renal tumor and a pancreatic tumor were ob-
served, and a 7 cm uterine myoma and a bladder
wall myoma were detected (Fig. 3). Esophagoga-
stroduodenoscopy (EGD) and endoscopic ultra-
sonography (EUS) revealed an esophageal leio-
myoma 20 mm in size in the area 20 cm away
from the incisor, and in the pancreatic head, a
tumor 6 mm in size was detected (Fig. 4). In
general positron emission tomography (PET),
increased fluorodeoxyglucose (FDG) uptake in the
Fig. 1. Parathyroid scan. Two foci of delayed washout of
the radiotracer in the bilateral parathyroid glnads (arrows).
Fig. 2. Sella MRI. Pituitary microadenoma (7 mm) at the
right lateral wing (arrow).Multiple Endocrine Neoplasia Type 1 with Multiple Leiomyomas
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pituitary was seen. Nonetheless, the increase of
the uptake by other lesions was not detected, and
thus indicated the benign nature of the multiple
tumors.
From the peripheral blood of the patient and
her mother, genomic DNA was extracted, and
sequencing of the MEN1 gene was performed.
Sequencing analysis revealed a transition of GAG
to GTG at codon 350 of exon 7, causing an amino
acid change from aspartic acid to valine, D350V
(Fig. 5).
Because of the detection of double parathyroid
adenoma, pituitary adenoma, pancreatic tumor,
and adrenal cortical tumor, as well as accom-
panying multiple leiomyomas in the bladder, the
uterus, and the esophagus, MEN1 was diagnosed.
For parathyroid adenoma, a subtotal parathyroi-
dectomy was performed, leaving half of the left
inferior parathyroid gland, and a prophylactic
thymectomy was performed as well. In postsur-
gical histological tests, the diagnosis of para-
thyroid adenoma was confirmed (Fig. 6). After
surgery, the intact-PTH level was decreased to
5.79 pg/mL. The remaining tumors are under
follow up observation.
DISCUSSION
MEN1 can be diagnosed by the identification of
two or more of the following: parathyroid tumor,
pancreatic islet cell tumor, and pituitary adenoma.
In addition, MEN1 may also include a carcinoid
tumor, lipoma, adrenal gland tumor, adrenal
Fig. 3. Abdomino-pelvic MRI. 2.3 cm-nodule in the left
adrenal gland, arrow (A), bladder wall mass (B), and
uterine myoma (C).
Fig. 4. Endoscopic ultrasonography
shows 6 mm sized round anechoic mass
at head of pancreas, suggesting pan-
creatic islet cell tumor (A), and 20 mm
sized homogenous hypoechoic mass,
suggesting esophageal leiomyoma (B).
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hyperplasia, and leiomyoma.
1-4 It is inherited
autosomal dominantly in most cases, and occurs
in familial or sporadic forms. In Korea, approxi-
mately 24 cases have been previously reported,
and among them, 11 cases were familial, and
cases with accompanying leiomyoma have not
been reported.
5-18 The clinicopathological features
of MEN1-associated tumors are generally similar
to those of tumors arising sporadically in the same
tissue; nevertheless, MEN1-associated tumors
show a distinct pattern in three aspects.
4 Firstly,
MEN1 develops in several endocrine tissues and
is multicentric. Due to its multicentric character-
istic, its recurrence rate after surgery is high.
Secondly, some MEN1 tumors (parathyroid and
gastrin cell) typically present approximately one
or more decades earlier than sporadic tumors of
the same tissue. Thirdly, some MEN1 tumors have
the potential for malignancy, and the pertinent
malignant tumors have been known to be a major
cause of death in MEN1 patients. The parathyroid
is the most prevalent endocrine organ affected,
and parathyroid involvement is seen in 90% of
patients.
1 In Korea, a tumor in the parathyroid
was seen in 83% of cases. In nine of these cases,
pathological findings were reported in the
literature, and 56% (5 cases) were parathyroid
hyperplasia, and 44% (4 cases) were parathyroid
adenoma (Table 1).
5-7,9-10,12-14,16-18
Pancreatic islet cell tumors are detected in
approximately 30 - 80% of MEN1 cases, and these
could be either functional or non-functional. In
the cases of functional tumors, it has been
reported that various hormones could be released.
In Korean MEN1 cases, a pancreatic islet cell
tumor was developed in 96% of the cases. Cases
secreting insulin (32%, 8 cases) and gastrin (20%,
5 cases) were most prevalent among functional
tumors. The cases considered to be non-functional
were 16% (4 cases) (Table 1).
5-18
Pituitary tumors, most commonly prolactino-
mas, are present in 10 - 50% of symptomatic
MEN1 patients. In Korean cases, a pituitary tumor
was detected in 75% of the cases, and among
them, prolactin-secreting adenoma was the most
prevalent, making up 68% (13 cases) (Table
1).
5,7-9,11,13-15,17,18
Other so-called non-classical neoplasms occur
1. Control/Normal 2. Proband
Fig. 5. Sequencing of exon 7 in the MEN1 gene shows a missense mutation (D350V).
Fig. 6. The parathyroid adenoma was composed of a
single cell proliferation of enlarged chief cells without any
fat cells present. The chief cells had clear to slightly
eosinophilic cytoplasm and round to oval nuclei with
heavy chromatin distribution. The cells are arranged in a
glandular and solid pattern (Hematoxlyin-eosin, × 200).Multiple Endocrine Neoplasia Type 1 with Multiple Leiomyomas 659
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frequently in MEN1 patients. Adrenal cortical
tumors are detected in approximately 40% of
Korean patients. The majority of these tumors
were bilateral, hyperplastic and non-functional,
and caused minimal morbidity. In addition to
endocrine tumors, non-endocrine mesenchymal
tumors, such as lipoma, angiofibroma, colla-
genoma, and leiomyoma, have been reported to
be associated with MEN1 and mutations in the
MEN1 gene.
2,19-21 Leiomyoma has been reported to
develop in the esophagus, lung, uterus, skin, and
ureter, and the difference from sporadic leio-
myoma is its multicentric development in many
cases.
2,3 In Korean reports, non-endocrine tumors
have only been reported in three cases: carcinoid
tumors (two cases) and leiomyomas (the current
study).
5-8,14
The MEN1 gene is localized to chromosome
11q13, was identified by positional cloning, and is
composed of 10 exons.
22,23 It encodes a 610 amino
acid protein, menin, which is localized primarily
to the nucleus.
23 Menin has a tumor-suppressor
function that involves direct binding to the JunD
protein and the inhibition of JunD-dependent
transcription.
24 Mutation sites in the MEN1 gene
are found throughout the entire coding region. A
genotype-phenotype correlation has not been
clearly established for the mutations, although it
has been suggested that some of the mutations
might be associated with the formation of specific
tumors.
25
In Korea, genetic analysis has been reported in
only 38% of MEN1 patients. This analysis is
summarized in Table 1, and a frameshift mutation
was detected in two cases, a nonsense mutation
in two cases, and a missense mutation in three
cases. In our case, a germline missense mutation,
D350V, was identified. To our knowledge, this
mutation has not been reported to date.
18,26-30
The first DNA analysis of a leiomyoma of the
esophagus in a patient with MEN1 failed to detect
allelic deletions at the MEN1 locus.
19 This implied
that the tumor arose through a completely
independent mechanism not associated with the
patient's underlying MEN1 disease. However, in a
study conducted subsequently, loss of hetero-
zygosity (LOH) at the MEN1 locus was shown in
two esophageal leiomyomas from a MEN1
patient.
20 Meanwhile, another study reported that
the MEN1 gene contributes to the development of
multiple esophageal and uterine leiomyomas in
MEN1 patients and that the gene does not play a
significant role in the tumorigenesis of sporadic
uterine leiomyoma.
2 Thus, leiomyomas in MEN1
and sporadic patients most likely develop through
different mechanisms.
In conclusion, although leiomyomas in MEN1
have not previously been reported in Korea, they
should be considered an integral part of MEN1
and examined carefully. Additionally, we found a
novel mutation, D350V, in exon 7 of the MEN1
gene.
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